Samsung Biologics

Activities: Pharmaceutical

Trending Articles

  1. Partnering for success: adaptable CDMO solutions for pharma, diagnostics, and biotech When it comes to liquid formulations and freeze-drying (lyophilisation) services, choosing a contract development and manufacturing organisation (CDMO) that prioritises...
  2. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows...
  3. WHO pandemic agreement determined after three years of negotiation Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks
  4. Common reasons why field certifiers fail accreditation Biosafety cabinets are the backbone of laboratory safety; however, many facilities encounter significant obstacles when using them, such as high energy consumption,...
  5. Beyond performance: GF’s SYGEF turns 50 PVDF piping systems continue to provide trusted solutions for demanding industries

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

Related Content

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Beyond capacity: biopharma companies need agile manufacturing partners

To succeed in the biopharmaceutical industry, organisations require a future-focused lens. What is in the clinical pipeline? What will demand look like in 5 years? When are key patents expiring and how will that impact competition?
Manufacturing

Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company

The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
Manufacturing

Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant

The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Cell & Gene Therapy

Samsung Biologics debuts a series of monoclonal antibody development platforms

These solutions aim to optimise the efficacy of monoclonal antibody therapies, while also minimising the presence of charged variants
Manufacturing

Navigating biologics chemistry, manufacturing and controls with an innovative CDMO

Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Samsung enters agreement on manufacture of antibody cancer drug

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance
Subscribe now